Oaknin A, Gladieff L, Martinez-Garcia J, Villacampa G, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 2023 Dec 1:S0140-6736(23)02405-4. doi: 10.1016/S0140-6736(23)02405.
PMID: 38048793